KR20160045726A - 면역조절제로서의 구형 핵산-기재 구축물 - Google Patents

면역조절제로서의 구형 핵산-기재 구축물 Download PDF

Info

Publication number
KR20160045726A
KR20160045726A KR1020167004851A KR20167004851A KR20160045726A KR 20160045726 A KR20160045726 A KR 20160045726A KR 1020167004851 A KR1020167004851 A KR 1020167004851A KR 20167004851 A KR20167004851 A KR 20167004851A KR 20160045726 A KR20160045726 A KR 20160045726A
Authority
KR
South Korea
Prior art keywords
average diameter
dna
nucleic acid
nanoscale
isp18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167004851A
Other languages
English (en)
Korean (ko)
Inventor
세르게이 그랴즈노프
크리스토퍼 씨. 메이더
티파니 엘. 할로
알렉산다르 필리프 라도비크-모레노
클레이턴 리셰
사가르 아난타트뮬라
Original Assignee
엑시큐어, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑시큐어, 인크. filed Critical 엑시큐어, 인크.
Publication of KR20160045726A publication Critical patent/KR20160045726A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A61K47/48861—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
KR1020167004851A 2013-07-25 2014-07-25 면역조절제로서의 구형 핵산-기재 구축물 Withdrawn KR20160045726A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361858584P 2013-07-25 2013-07-25
US61/858,584 2013-07-25
PCT/US2014/048294 WO2015013675A1 (en) 2013-07-25 2014-07-25 Spherical nucleic acid-based constructs as immunoregulatory agents

Publications (1)

Publication Number Publication Date
KR20160045726A true KR20160045726A (ko) 2016-04-27

Family

ID=51422128

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167004851A Withdrawn KR20160045726A (ko) 2013-07-25 2014-07-25 면역조절제로서의 구형 핵산-기재 구축물

Country Status (8)

Country Link
US (1) US20160194642A1 (enExample)
EP (1) EP3024494A1 (enExample)
JP (1) JP2016534094A (enExample)
KR (1) KR20160045726A (enExample)
CN (1) CN105658241A (enExample)
AU (1) AU2014292928A1 (enExample)
CA (1) CA2919273A1 (enExample)
WO (1) WO2015013675A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
JP5863670B2 (ja) 2010-01-19 2016-02-17 ノースウェスタン ユニバーシティ 核酸および／または他の構成要素を含有している合成ナノ構造体
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
CN112107693B (zh) 2013-12-03 2023-05-26 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
CA2953216C (en) * 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US10704043B2 (en) * 2015-01-14 2020-07-07 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2016134104A1 (en) * 2015-02-18 2016-08-25 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
WO2016149323A1 (en) * 2015-03-16 2016-09-22 Exicure, Inc. Immunomodulatory spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP3322407A4 (en) * 2015-07-14 2019-07-10 Exicure, Inc. RELOCATION OF LIPID COMPLEXES IN CELLS INDUCED BY SPINICAL NUCLEIC ACIDS (SNA)
AU2017261360A1 (en) 2016-05-06 2018-11-29 Exicure Operating Company Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018213585A1 (en) * 2017-05-17 2018-11-22 Northwestern University Conjugation of peptides to spherical nucleic acids (snas) using tracelless linkers
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
JP7023460B2 (ja) * 2017-10-26 2022-02-22 国立大学法人 鹿児島大学 Ｔｌｒリガンド固定化ナノ粒子
US20210189397A1 (en) * 2018-05-10 2021-06-24 Northwestern University Self-manageable abnormal scar treatment with spherical nucleic acid (sna) technology
US20210269806A1 (en) * 2018-06-20 2021-09-02 Exicure, Inc. Il-1 beta targeting spherical nucleic acids
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US11951211B2 (en) * 2020-01-31 2024-04-09 Yale University DNA brick-assisted liposome sorting
CN120615126A (zh) * 2022-12-09 2025-09-09 武田药品工业株式会社 经修饰的免疫调节剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472881A (en) 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
CA2262018C (en) 1996-07-29 2007-10-02 Nanosphere Llc Nanoparticles having oligonucleotides attached thereto and uses therefor
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
AU784040B2 (en) 1999-06-25 2006-01-19 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2001051665A2 (en) 2000-01-13 2001-07-19 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
ATE487136T1 (de) 2000-03-28 2010-11-15 Nanosphere Inc Nanopartikel mit gebundenen oligonukleotiden und verwendungen derselben
US7238472B2 (en) 2001-05-25 2007-07-03 Nanosphere, Inc. Non-alloying core shell nanoparticles
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
AU2008212820B2 (en) 2007-02-09 2014-01-30 Northwestern University Particles for detecting intracellular targets
WO2008127789A2 (en) 2007-02-27 2008-10-23 Northwestern University Molecule attachment to nanoparticles
DK2160464T3 (da) 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
CA2732142A1 (en) * 2008-07-28 2010-02-04 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 9 expression by antisense oligonucleotides
EP2365803B1 (en) 2008-11-24 2017-11-01 Northwestern University Polyvalent rna-nanoparticle compositions
CN102307470B (zh) 2009-01-08 2015-05-20 西北大学 通过多价寡核苷酸修饰的纳米颗粒缀合物抑制细菌蛋白的产生
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100294952A1 (en) 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
US20120277283A1 (en) 2009-08-04 2012-11-01 Mirkin Chad A Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications
US20120269730A1 (en) 2009-08-07 2012-10-25 Northwestern University Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
US9376690B2 (en) 2009-10-30 2016-06-28 Northwestern University Templated nanoconjugates
US20130178610A1 (en) 2009-12-24 2013-07-11 Chad A. Mirkin Oligonucleotide specific uptake of nanoconjugates
EP2399608B1 (en) * 2010-03-05 2020-07-08 Sebastian Fuchs Immunomodulating nanoparticulate composition for use in inhalation therapy

Also Published As

Publication number Publication date
US20160194642A1 (en) 2016-07-07
CA2919273A1 (en) 2015-01-29
CN105658241A (zh) 2016-06-08
AU2014292928A1 (en) 2016-03-03
WO2015013675A9 (en) 2016-04-28
EP3024494A1 (en) 2016-06-01
JP2016534094A (ja) 2016-11-04
WO2015013675A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
KR20160045726A (ko) 면역조절제로서의 구형 핵산-기재 구축물
JP6697384B2 (ja) 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
US20170175121A1 (en) Self assembling nucleic acid nanostructures
US11957788B2 (en) Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
BRPI0719445A2 (pt) Composições de ligandos de tlr e antivirais.
JP5930146B2 (ja) 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
HK1131635A (en) Compositions of tlr ligands and antivirals

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid